PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.

Zacks Investment Research • Jul 9, 2026

SRPT or PRTA: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jun 24, 2026

Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment

PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.

Zacks Investment Research • May 8, 2026

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the first quarter of 2026 and provided business highlights.

Business Wire • May 7, 2026

Prothena to Report First Quarter 2026 Financial Results on May 7

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that it will report its first quarter 2026 financial results on Thursday, May 7, 2026, after close of the U.S. financial markets.

Business Wire • Apr 30, 2026

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy.

Business Wire • Apr 27, 2026

Prothena Announces Leadership Team Updates

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena promoting Ms. Kingston to Chief Strategy Officer and Mr. Isaacs to General Counsel and Corporate Secretary. Mr. Malecek is departing in June.

Business Wire • Apr 10, 2026

Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet

The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Mar 26, 2026

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for prasinezumab for Parkinson's and BMS-986446 for Alzheimer's disease at AD/PD™ 2026.

Business Wire • Mar 21, 2026

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM.

Business Wire • Mar 9, 2026